Article in Journal of medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 16 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Zhongzhi WuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Lubing GuDepartment of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
Sicheng ZhangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.
Tao LiuDepartment of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
Pradeep B LukkaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0001-8034-7810
Bernd MeibohmDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0003-3923-3648
John C BollingerDepartment of Structural Biology, Biomolecular X-Ray Crystallography Center, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
Muxiang ZhouDepartment of Pediatrics and Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia 30322, United States.
Wei LiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States.ORCID 0000-0002-9522-4474
University of Tennessee Health Science Center · USEmory University · USSt. Jude Children's Research Hospital · US
Funding
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancerR01CA240447 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI, ZHOU, MUXIANG · 2020 to 2024
$2.7M
Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactionsR01CA180519 · NCI · GEORGIA STATE UNIVERSITY · PI WANG, BINGHE, ZHOU, MUXIANG · 2014 to 2018
$2.2M
Selective Targeting Survivin for Cancer TherapyR01CA193609 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2016 to 2020
$1.9M
Feasibility study of developing SEAK-114 for the treatment of pediatric cancersR43CA257324 · NCI · SEAK THERAPEUTICS, LLC · PI LI, WEI, WU, ZHONGZHI · 2020 to 2020
$400k
Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancersR43CA246788 · NCI · SEAK THERAPEUTICS, LLC · PI WU, ZHONGZHI · 2019 to 2020
$355k
Acquisition of a Q-TOF Mass SpectrometerS10OD010678 · OD · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2012 to 2012
$325k
Mass Spectrometer for Small Molecule Drug DevelopmentS10OD016226 · OD · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MEIBOHM, BERND · 2014 to 2014
$316k
Acquisition of a 400MHz Solution NMR System with an AutosamplerS10RR026377 · NCRR · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, WEI · 2010 to 2010
Murine double minute 2 (MDM2) and X-linked inhibitor of apoptosis protein (XIAP) are important cell survival proteins in tumor cells. As a dual MDM2/XIAP inhibitor reported previously, compound MX69 has low potency with an IC
Indexed as
AnimalsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMaleMolecular Docking SimulationProtein BindingProto-Oncogene Proteins c-mdm2QuinolinesRatsRats, Sprague-DawleySulfonamidesX-Linked Inhibitor of Apoptosis ProteinMDM2 protein, humanProto-Oncogene Proteins c-mdm2QuinolinesSulfonamidesXIAP protein, humanX-Linked Inhibitor of Apoptosis Protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.